Leishmaniasis is a protozoan disease transmitted through the bite of a sandfly infected with leishmania parasites. Visceral leishmaniasis, also known as kala-azar, is a systemic disease, and it is usually diagnosed by the presence the organisms in the spleen, lymph gland, or bone marrow aspirates. Cutaneous leishmaniasis usually occurs in the form of an ulcerated nodule on the skin Patients with lesions on the face or another cosmetically important area should be treated to reduce the size of the resultant scar. The most successful therapy is intralesional therapy. Systemic chemotherapy is recommended for very extensive lesions. Uncomplicated lesions do not need to be treated aggressively. Simple excision, cryosurgery, and topical therapy are usually sufficient.
- Aronson NE, Wortmann GW, Byrne WR, Howard RS, et al. A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl Trop Dis. 2010;9(3):e628. doi: 10.1371/journal.pntd.0000628. Pubmed PMID.CrossRefGoogle Scholar
- Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (glucantime) vs cryotherapy and intralesional meglumine antimoniate (glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol. 2004;43:281–3.CrossRefGoogle Scholar
- Davidson RN. AIDS and leishmaniasis. Genitourin Med. 1997;10:298–9.Google Scholar
- Gürel MS, Tatlı M, Özbilge H, et al. Efficacy of cryotherapy and intralesional pentostam in treatment of cutaneous leishmaniasis. J Egypt Soc Parasitol. 2000;30:169–76.Google Scholar
- Higashi GI. Vaccines for parasitic diseases. Ann Rev Public Health. 1988;10:560–86.Google Scholar
- Kochar DK, Aseri S, Sharma BV, Bumb RA, et al. The role of rifampicin in the management of cutaneous leishmaniasis. OJM. 2000;93:733–7.Google Scholar